These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32975600)

  • 21. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
    Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT.
    Schaefer N; Grözinger G; Pech M; Pfammatter T; Soydal C; Arnold D; Kolligs F; Maleux G; Munneke G; Peynircioglu B; Sangro B; Pereira H; Zeka B; de Jong N; Helmberger T;
    Clin Colorectal Cancer; 2022 Dec; 21(4):285-296. PubMed ID: 36270925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (90)Y-glass microspheres for hepatic neoplasia.
    Mahnken AH
    Future Oncol; 2015; 11(9):1343-54. PubMed ID: 25952780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma.
    Labgaa I; Tabrizian P; Titano J; Kim E; Thung SN; Florman S; Schwartz M; Melloul E
    HPB (Oxford); 2019 Nov; 21(11):1497-1504. PubMed ID: 31005494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation.
    Zori AG; Ismael MN; Limaye AR; Firpi R; Morelli G; Soldevila-Pico C; Suman A; Vogel JD; Lazarowicz M; Geller BS; Toskich B; Gonzalo DH; Johnson MW; Cabrera R
    Am J Clin Oncol; 2020 May; 43(5):325-333. PubMed ID: 32079854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; De Hertogh G; Deroose CM; Bonne L; Vandevaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1882-1890. PubMed ID: 28685382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioembolization for the treatment of hepatocellular carcinoma.
    Kim HC
    Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors.
    Sharma NK; Kappadath SC; Chuong M; Folkert M; Gibbs P; Jabbour SK; Jeyarajah DR; Kennedy A; Liu D; Meyer JE; Mikell J; Patel RS; Yang G; Mourtada F
    Brachytherapy; 2022; 21(5):569-591. PubMed ID: 35599080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trans-Arterial Radioembolization with Yttrium-90 of Unresectable and Systemic Chemotherapy Resistant Hepatoblastoma in Three Toddlers.
    Balli HT; Aikimbaev K; Guney IB; Piskin FC; Yagci-Kupeli B; Kupeli S; Kanmaz T
    Cardiovasc Intervent Radiol; 2022 Mar; 45(3):344-348. PubMed ID: 35034139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases.
    Cook K; Gupta D; Liu Y; Miller-Rosales C; Wei F; Tuttle E; Katz SC; Marshak R; Kim AY
    Curr Med Res Opin; 2024 Apr; 40(4):591-598. PubMed ID: 38414420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma.
    Zarca K; Mimouni M; Pereira H; Chatellier G; Vilgrain V; Durand-Zaleski I;
    Clin Ther; 2021 Jul; 43(7):1201-1212. PubMed ID: 34059326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial Radioembolization (TARE) Agents beyond
    Bouvry C; Palard X; Edeline J; Ardisson V; Loyer P; Garin E; Lepareur N
    Biomed Res Int; 2018; 2018():1435302. PubMed ID: 30687734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison.
    Agirrezabal I; Bouattour M; Pinato DJ; D'Alessio A; Brennan VK; Carion PL; Shergill S; Amoury N; Vilgrain V
    Eur J Cancer; 2024 Jan; 196():113427. PubMed ID: 37988840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma.
    Iñarrairaegui M; Pardo F; Bilbao JI; Rotellar F; Benito A; D'Avola D; Herrero JI; Rodriguez M; Martí P; Zozaya G; Dominguez I; Quiroga J; Sangro B
    Eur J Surg Oncol; 2012 Jul; 38(7):594-601. PubMed ID: 22440743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.